The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
- Registration Number
- NCT05836948
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Brief Summary
This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 174
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;
- Have at least one measurable tumor lesion per RECIST v1.1;
- ECOG performance status of 0-1;
- Life expectancy ≥ 12 weeks;
- Adequate bone marrow and organ function;
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
- Patients with active central nervous system metastases or meningeal metastases;
- Received anti-tumor treatment such as chemotherapy, biotherapy, targeted therapy, immunotherapy, radical radiotherapy, or other unlisted clinical research drugs or treatments within 4 weeks prior to the first use of the study drug;
- History of serious cardiovascular and cerebrovascular diseases;
- Subjects who received>30Gy of radiation therapy within 4 weeks before the first medication, and those who received ≤ 30Gy of palliative radiation therapy within 7 days before the first medication;
- Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SHR-9839 SHR-9839 three stages: dose escalation, dose expansion and efficacy expansion.
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) or maximum administered dose (MAD) On the first day of each week,4 weeks is a treatment cycle Incidence and category of dose limiting toxicities (DLTs) during the first 4 week cycle of SHR-9839 treatment
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0) From Day 1 to 90 days after last dose Assess safety and tolerability of SHR-9839 by way of adverse events (CTCAE v5.0).
Recommended Phase 2 dose (RP2D) From Day 1 to 90 days after last dose RP2D will be determined on the basis of evaluation on MTD/MAD, PK, PD, efficacy data in dose escalation and dose expansion stages.
- Secondary Outcome Measures
Name Time Method PK parameter: Tmax of SHR-9839 approximately 10 months Time to maximum concentration of SHR-9839
PK parameter: AUC0-t of SHR-9839 Approximately 10 months Area under the concentration-time curve from time 0 to the last measurable concentration time point of SHR-9839
PK parameter: AUC0-∞ of SHR-9839 Approximately 10 months Area under the concentration-time curve from time 0 to infinity of SHR-9839
Duration of response (DoR) Approximately within 36 months Evaluated using RECIST 1.1
Disease control rate (DCR) Approximately within 36 months Evaluated using RECIST 1.1
PK parameter: Cmax of SHR-9839 approximately 10 months Maximum concentration of SHR-9839
Immunogenicity of SHR-9839 Approximately 12 months Anti-SHR-9839 antibody (ADA)
Overall response rate (ORR) Approximately within 36 months Evaluated using RECIST 1.1
Progression-free survival (PFS) Approximately within 36 months Evaluated using RECIST 1.1
Trial Locations
- Locations (1)
Zhejiang Tumor Hospital
🇨🇳Hangzhou, Zhejiang, China